• Japanese
  • Korean
  • Chinese
Cover Image

China Independent Clinical Laboratory Industry Report, 2013-2015

Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clinical laboratory market only values RMB2.5-3 billion, equivalent to 2%-3% of the total revenue of medical diagnosis, much lower than 30% in developed countries.

However, in the context of Chinese medical reform, the cost control of public hospitals, the increasing number of patients that primary medical institutions are confronted with, the rapid development of private hospitals and other factors will greatly boost China independent clinical laboratory industry which will grow at a rate over 40%.

The report focuses on the operation, advantages and characteristics of 10 major independent clinical laboratory companies in China on the basis of an analysis on the development environment, the market situation, the competition pattern, the impact of upstream and downstream as well as the prospect of China independent clinical laboratory industry.

In China, among about 110 laboratories engaged in independent medical diagnosis, top four ones, namely Kingmed Diagnostics, ADICON, DiAn Diagnostics and DaAn Health, master more than 70% domestic market share together, all with the chain integrated diagnostic service mode.

As a giant in China independent clinical laboratory industry, Kingmed Diagnostics has maintained a revenue growth rate of more than 50% in the past five years. It achieved the revenue of over RMB1 billion in 2012 with 21 laboratories, over 13,000 clients (including more than 1,000 Grade-A hospitals) and 1,600 types of inspection services. Moreover, the company has received two rounds of capital injection from Lenovo, and always stood at the leading position of the industry.

ADICON and DiAn Diagnostics are located in the second echelon in the industry.

ADICON targets at the high-end field (including 220 special inspection items), with 15 laboratories, only second to Kingmed Diagnostics. In June 2012, the subsidiary Hefei ADICON became a designated cervical and breast cancer diagnosis institution in Hefei by virtue of the strong and efficient diagnostic service network.

China's first listed independent clinical laboratory enterprise DiAn Diagnostics gained the revenue of RMB414 million from independent medical diagnostic services in 2012, up 52.2% year on year. DiAn Diagnostics shows significant unique competitive advantages, reflected in hierarchical management and "agency + services" business model. As of the end of 2012, DiAn Diagnostics owned 13 independent diagnostic laboratories, and planned to establish 15 Class-A laboratories and 30 Class-B ones by 2016 for the purpose of the overall improvement in the service response speed.

Table of Contents

1 Overview of Independent Medical Diagnosis

  • 1.1 Definition
  • 1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry

  • 2.1 Policy
    • 2.1.1 Access Policy
    • 2.1.2 Industrial Policy
  • 2.2 Impact of International Market
    • 2.2.1 Market Situation
    • 2.2.2 Key Enterprises
  • 2.3 Status Quo
  • 2.4 Competition Pattern
  • 2.5 Development Prospect and Trend

3 Upstream and Downstream of China Independent Clinical Laboratory Industry

  • 3.1 Impact of Upstream Market
    • 3.1.1 Market Situation
    • 3.1.2 Competition Pattern
  • 3.2 Impact of Downstream Development
    • 3.2.1 Huge Independent Medical Diagnosis Market
    • 3.2.2 Health Care Reform Propels the Rapid Development of the Independent Medical Diagnosis Market
    • 3.2.3 Diversified Demand Will Promote the Upgrading of the Independent Clinical Laboratory Industry

4 Major Independent Clinical Laboratory Enterprises in China

  • 4.1 Kingmed Diagnostics
    • 4.1.1 Profile
    • 4.1.2 Status Quo and Prospect
  • 4.2 Hangzhou ADICON
  • 4.3 DiAn Diagnostics
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Business Structure
    • 4.3.4 Gross Margin
    • 4.3.5 Clients and Suppliers
    • 4.3.6 R & D and Investment
    • 4.3.7 Independent Medical Diagnostic Services
    • 4.3.8 Development Prospect and Trend
  • 4.4 Da An Gene
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Gross Margin
    • 4.4.5 Clients and Suppliers
    • 4.4.6 R & D
    • 4.4.7 Independent Medical Diagnostic Services
  • 4.5 Beijing NYMPHAVN
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Clients
    • 4.5.6 R & D and Investment
  • 4.6 CapitalBio
  • 4.7 Beijing Adinovo
  • 4.8 Hangzhou Zhiyuan
  • 4.9 Kindstar Global (Beijing)
  • 4.10 Deyi Diagnostics

Selected Charts

  • Schematic Diagram of Independent Medical Diagnostic Industry Chain
  • Comparison between China and the U.S. in Medical Diagnosis Providers
  • Relevant Policies of China Independent Medical Diagnostic Industry, 2010-2012
  • Market Share of the U.S. Independent Medical Inspection Industry by Item
  • U.S. Medical Inspection Market Share (by Provider)
  • Revenue and Operating Profit of Quest Diagnostics, 2007-2013
  • Revenue Structure of Quest Diagnostics (by Business), 2011-2012
  • Major M & A Events of Quest Diagnostics, 2006-2013
  • Sales and Operating Profit of Labcorp, 2007-2013
  • Revenue of Labcorp (by Business), 2009-2013
  • Major M & A Events of Labcorp, 2007-2012
  • Comparison between Massachusetts General Hospital and One Chinese Grade-A Hospital in Top Five Outbound Inspection Items
  • Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, by the end of 2012
  • Market Scale and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2015E
  • Market Scale and Growth Rate of In Vitro Diagnostic Reagents in China, 2007-2015E
  • Structure of In Vitro Diagnostic Reagents in China, 2012
  • Chinese In Vitro Diagnostic Reagent Market Segments, 2012
  • Business and Inspection Revenue of Medical Institutions in China, 2010
  • Number of Patients of Hospitals and Primary Health Care Institutions in China, 2008-2012
  • Number of Public and Private Hospitals in China, 2008-2012
  • Revenue and YoY Growth Rate of Kingmed Diagnostics, 2008-2012
  • Distribution and Establishment Time of Independent Medical Laboratories of Hangzhou ADICON
  • Layout of Independent Diagnostic Laboratories of DiAn Diagnostics, by the end of 2012
  • Revenue and Profit of DiAn Diagnostics, 2008-2013
  • Revenue and Net Income of Top Five Subsidiaries of DiAn Diagnostics, 2011-2012
  • Revenue of DiAn Diagnostics (by Business), 2008-2013
  • Revenue Structure of DiAn Diagnostics (by Business), 2008-2013
  • Revenue of DiAn Diagnostics (by Region), 2008-2011
  • Revenue of DiAn Diagnostics (by Region), 2011-2013
  • Gross Margin of DiAn Diagnostics (by Business), 2008-2013
  • Revenue of DiAn Diagnostics from Top 5 Clients and % of Total Revenue, 2008-2013
  • Name List and Revenue Contribution of Top 5 Clients of DiAn Diagnostics, 2010-2013
  • Procurement of DiAn Diagnostics from Top 5 Suppliers and % of Total Procurement, 2008-2012
  • Name List and Procurement of Top 5 Suppliers of DiAn Diagnostics, 2009-2011
  • R&D Costs and % of Total Revenue of DiAn Diagnostics, 2008-2013
  • Revenue and Gross Margin of Independent Diagnostic Business of DiAn Diagnostic, 2008-2013
  • Revenue and Gross Margin of Independent Diagnostic Business of DiAn Diagnostic (by Product), 2008-2012
  • Revenue Percentage of Independent Diagnostic Business of DiAn Diagnostics (by Client), 2010-2012
  • Revenue and Operating Income of DiAn Diagnostics, 2012-2015E
  • Revenue and Profit of Da An Gene, 2008-2013
  • Revenue of Da An Gene (by Product), 2008-2012
  • Revenue Structure of Da An Gene (by Region), 2008-2012
  • Gross Margin of Da An Gene (by Product), 2008-2012
  • Name List and Revenue Contribution of Top 5 Clients of Da An Gene, 2012
  • Name List and Procurement of Top 5 Suppliers of Da An Gene, 2012
  • R&D Costs and % of Total Revenue of Da An Gene, 2010-2012
  • Revenue and Gross Margin of Medical Laboratory Services of Da An Gene, 2008-2012
  • Registered Capital, Revenue and Net Income of Medical Laboratory Subsidiaries of Da An Gene, 2012
  • Revenue and Profit of NYMPHAVN, 2009-2013
  • Revenue of NYMPHAVN (by Product), 2009-2013
  • Revenue of NYMPHAVN (by Region), 2010-2012
  • Gross Margin of NYMPHAVN (by Product), 2009-2013
  • NYMPHAVN's Revenue from Top 5 Clients and % of Total Revenue, 2009-2013
  • Name List and Revenue Contribution of NYMPHAVN's Top 5 Clients, 2012-2013
  • R&D Costs and % of Total Revenue of NYMPHAVN, 2009-2012
  • Some Strategic Copartners of Adinovo
  • Major Events of Kindstar Global

Related Companies

  • Daan Gene Co.,Ltd.of Sun Yat-Sen University(002030.SZ)
  • Zhejiang D.A. Diagnostics Co., Ltd(300244.SZ)
Show More
Pricing
Get Notified
Email me when related reports are published